and Advisory Services Geneve Switzerland Gershon Capital amp Cie Gershon amp Company Strategic Guidance amp Capital Gershon Capital is a boutique Swiss investment firm that provides advisory services and capital raising solutions for emerging healthca ID: 759879
Download Presentation The PPT/PDF document "Healthcare Investment Banking" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Healthcare Investment Banking and Advisory Services Geneve, Switzerland
Gershon
Capital &
Cie
________
Gershon &
Company
Slide2Strategic Guidance & Capital
Gershon Capital is a boutique Swiss investment firm that provides advisory services and capital raising solutions for emerging healthcare and life science companies. We work with the highest quality companies and syndicate deals to the most prominent institutional investors in Europe and in the U.S. alongside our direct investment.
Slide3Scientific, Medical & Regulatory Expertise
We leverage 20 years of experience in science, medicine, regulatory affairs and finance to analyze companies at a highly technical level. This detailed analysis and due-diligence process defines our strategy and gives investors a high level of confidence that companies we work with will be successful.
Slide4Strong Relationships & Professional Networks
Our long-standing relationships and professional affiliations with many of the most respected institutional investment funds, academic centers and industry leaders allows us to provide high-level strategic consulting, technical advisory services, and deal syndication.
Slide5Clients
Pictet & CieSectoral Asset ManagementStandard & Poor’sUBSSG CowenFidelity InvestmentsFranklin TempletonWarburg PincusGerson LehrmanForest LabsGlaxoSmithKlineTexas Pacific Group
Merrill Lynch
Brown Brothers HarrimanCaxton AssociatesFederal Reserve Board of GovernorsGoldman Sachs Distressed Assets GroupGoldman Sachs Special Situations Group Goldman Sachs AsiaBain Capital Private Equity
Leerink Swann
Highline Capital
American Express
Clinton Foundation
Senator John Kerry
Senator John Edwards
AIG Global
Stark Investments
Barclays Bank
Ziff Brothers Investments
Putnam Investments
Tisbury Capital
McKinsey & Co
Slide6Institutional and Strategic Syndicate Investors in Our Network
AbingworthAdventApax PartnersAravais VenturesBain CapitalBB BiotechBB MedtehBellevue GroupBristol-Myers SquibbCaxton VenturesD.E. ShawEdmond de RothschildEli LillyEssex Woodlands
General Atlantic
Global Life SciencesHBM BioventuesHLM Venture PartnersHighland CapitalIndex VenturesJohnson & JohnsonLBO FranceLombard OdierMayfieldMerckMPM CapitalNextech VenturesVI Partners
Nomura Phase4
Novo Ventures
Novartis Venture Fund
Pictet & Cie
Sectoral Asset
Mgmnt
Societe
Generale
Versant Ventures
Thomas,
McNerney
TPG
TVM
Venrock
Warburg
Pincus
Wellington Partners
Ysios
Slide7Investment Banking
Gershon Capital provides direct investment and deal syndication for emerging healthcare and life science companies. The firm provides both strategic and quantitative services to identify new healthcare investment opportunities, lead due diligence on prospective investments, provide technical, scientific and financial analysis, arrange investor meetings, negotiate with syndicated investors and counsel, and structure and close the transaction.
Slide8Investment Strategy
The firm seeks to work with healthcare and life science companies with therapeutic or medical device products that meet unmet clinical needs.
Our average syndicated deal is between $10M – $50M USD in Series B private companies and $25M – $100M USD in micro-cap public companies. Our clients
typically
poses
the following attributes:
- Breakthrough technology based on strong science
- Experienced and well-rounded management team with a proven track record in successfully commercializing new products and technologies
- Strong and comprehensive IP portfolio
- Partnerships with leading academic institutions and strategic players
- Product or technology that permits company valuation at exit to be between $150M and $750M USD within three to five years of investment
Slide9Rigorous Due Diligence Process
Gershon
Capital adheres to a extensive and disciplined, multi-phase due diligence process that includes rigorous industry analysis and the development of customized solutions for investors and companies.
Deal evaluation includes analysis of corporate management, corporate finances, assessment of underlying scientific and medical principles, clinical applications, clinical study design, drug and device approval feasibility, intellectual property, commercial application, and pricing, reimbursement, and analysis of regulatory, legal, and economic changes that affect market dynamics and competitive landscapes.
Slide10Vertically Integrated Investment and Advisory Firm
With our new collaboration with CRT and Nordberg Capital we are now a fully vertically integrated investment firm offering a broad array of capital raising solutions and advisory services for early stage healthcare companies including access to the IPO market, trading and market making capabilities, PIPEs, special purpose acquisition companies (SPACs), convertible offerings and private placement of debt and equity, and customized solutions for middle-market companies including financial restructuring, structuring and execution of senior and subordinated debt, mergers, acquisitions, fairness opinions, joint ventures and takeover defense.
Our integrated networks from these collaborations allows us to access over 1000 investors in the US, Europe, Scandinavia, and Russia.
Slide11Advisory Services
Gershon Capital aims to add value to its portfolio companies through its relationship with Gershon & Company, our consulting arm. The Gershon & Company advisory group leverages its senior management team and industry networks to bring sector expertise, investment experience, and regulatory, scientific and medical knowledge to our emerging healthcare and lifescience companies. Core Services:
FDA Regulatory
Affairs and
Compliance
FDA Filings for Drugs and Devices
Reimbursement and Pricing Assessment
CMS and Private Payer Insurance Coding and Reimbursement Development
Clinical Trial Design and Analysis
Patent
Filings
Intellectual Property Review
Business Plan Development
Valuation Modeling
Competitive Market Analysis
Private Placement Memorandum (PPM) Development
Business Development: Licensing & Commercialization
Development of Multi-Media Sales and Marketing Road Shows in Europe and the U.S.
Slide12Regulatory
FDA Regulatory Affairs and Compliance
FDA Filings: Prepare and submit IND, ANDA, NDA, DMF, 510k, PMA
Quality Assurance (QA) and Quality Control (QC) analysis and oversight
Regulatory compliance review of product labeling, advertising, and promotional materials (GPP)
Reimbursement and Pricing Assessment
Centers for Medicare and Medicaid Services (CMS) coding and reimbursement
Private Payer coding and reimbursement
EU, UK, and Japanese coding and reimbursement
Clinical Trial Design and Analysis
Good Clinical Practice(GCP) protocol design and monitoring
Data handling, monitoring, and record keeping
Reporting and submission compliance
Slide13Intellectual Property
Patent Filings
Patent quality and claim scope
Prior art search and competitive product analysis
Freedom to operate review
Patent Litigation
Analysis of infringement and invalidity
US
EU, UK, and Japan
Strategic IP Review and Analysis
Patent value analysis utilizing market models and case law
Verification of patent use in the global markets
Strategic IP industry partnership development
Slide14Financial
Valuation Modeling
Competitive Market Analysis
Business Plan Development
Private Placement Memorandum (PPM) Development
Business Development: Licensing & Commercialization
Access to the IPO market, trading and market making capabilities, PIPEs, special purpose acquisition companies (SPACs)
Customized solutions for middle-market companies including financial restructuring, structuring and execution of senior and subordinated debt, mergers, acquisitions, fairness opinions, joint ventures and takeover defense
Slide15Investor Relations
Multi-Media Sales and Marketing Investor Road Show in Europe and the United States
Pre Road Show
Optimization of investor materials and presentation driven by detailed scientific, medical, regulatory, and financial review and analysis
Road Show
Organization and digital video production of a five city European road show in major financial centers
Post Road Show/Ongoing Outbound Marketing
Investor follow up assessing ongoing investor sentiment
Digital video syndication campaign to prominent online financial journals
Other Customized Video, Internet, Multi-Media Marketing Solutions
Slide16Dave Gershon, MD, JD, MPH
Dave Gershon is the Senior Partner of Gershon & Company and its subsidiary Gershon Capital, Chairman of the National Institute for Healthcare Economics and Regulatory Policy, is a designated Standard & Poor’s ‘Healthcare Industry Leader’, Adjunct Professor of Healthcare Economics and Policy at Johns Hopkins University, Visiting Lecturer Healthcare Finance and Drug Development at Harvard University/MIT Sloan School of Business, and an Aspen Institute Senior Fellow and Chair of the Aspen Institute Business of Health Program.
Dr. Gershon is a successful entrepreneur with two successful start-ups and over 20 years experience as an oncologist-immunologist, clinical researcher, healthcare economist, and FDA and CMS healthcare regulatory attorney with expertise in drug and medical device approval processes, intellectual property, clinical research, and reimbursement for pharmaceuticals, medical devices, and healthcare services.
He currently serves on the Advisory Board of Pictet & Cie, one of the largest Swiss private banks with $400 billion dollars under management, and the Advisory Board of Sectoral Asset Management, the leading life sciences hedge fund and member of the State Street Global Alliance with $4 billion dollars in assets under management, exclusively investing in public and private pharmaceutical, biotechnology, generics, medical device, and medical technology companies.
Slide17Justin Schreiber
Justin Schreiber is a partner at
Gershon
Capital and is an entrepreneur with an expertise in management, IT and digital media. He was the former President of
OneMedForum
, an emerging healthcare and finance forum that hosts conferences for early stage private and public
lifescience
companies surrounding the JP Morgan conference in San Francisco. Under his leadership the conference has grown to be one of the largest and most successful emerging healthcare finance forums in the US. Prior to this Mr. Schreiber served as Director of Business Development for
Tefen
USA, a global life sciences consultancy. He began his career working as a financial specialist for Gain Capital, a leading provider of online foreign exchange trading, asset management, and B2B
forex
services.
Mr. Schreiber evaluates deals in healthcare IT and biotechnology and directs our investor relations and digital media group.
He holds a BS in International Business from Elizabethtown College and a BA in International Management from the ICN
École
de management in Nancy, France.
Slide18Contact Information
Dave Gershon, MD, JD, MPH
Direct: +1.646.472.5731
Mobile: +1.646.233.6757
dgershon@gershoncapital.com
Justin Schreiber
Mobile: +1.717.381.7492
jschreiber@gershoncapital.com
Website: www.GershonCapital.com